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Sara Wouters1*, Linda De Meirleir2, Edward Campforts1 and Annik Lampo1Abstract
Niemann-Pick disease type C (NP-C) is a rare autosomal-recessively inherited lysosomal storage disorder. It is caused
by mutations in the NPC1 (95%) or NPC2 gene. It is a progressive and highly heterogeneous disease, characterized
by the presentation of visceral, neurological, and psychiatric symptoms.
Apart from the patients that die early from organic failure, most of the patients with juvenile and adolescent/adult
onset of the disease, develop neurological and psychiatric symptoms. In some cases psychiatric signs, mostly
psychosis, can be the first sign of the disease. A delay in diagnosis is often seen.
By describing the case of a 16-year old girl, we would like to highlight current opinion about NP-C disease and
resume recent findings on the clinical presentation, diagnosis and treatment. We focus on the psychiatric signs, and
most important the specific combinations that are typical for the disease.
There is no curative treatment for NP-C. Miglustat is used to modify neurological signs in NP-C.
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Niemann-Pick disease type C (NP-C) is a rare autosomal-
recessively inherited lysosomal storage disorder. It is
caused by mutations in the NPC1 (95%) or NPC2 gene.
The gene-mutations give characteristic abnormalities in
the intracellular transport of endocytosed cholesterol with
sequestration of unesterified cholesterol in lysosomes and
late endosomes. These trafficking defects also cause accu-
mulation of glycosphingolipids in various tissues, includ-
ing the brain. The estimated incidence of diagnosis is of
1:100,000-120,000 live births [1,2].
NP-C is a neurovisceral disease, with a highly heteroge-
neous presentation and is characterized by progressive
neurological deterioration and early death. Patients can
show visceral, neurological and psychiatric manifestations
which present alone or in different combinations [1-4].
NP-C disorder is chronic, but has a great variation in age
of onset and disease course [2,4-7]. Niemann-Pick type C
often remains undetected for many years. There is an
average delay in diagnosis of 5–6 years from onset of the
neurological symptoms [1,8,9]. The course towards a* Correspondence: sara.wouters@uzbrussel.be
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unless otherwise stated.diagnosis even tends to be longer, when the first presenta-
tion is a psychiatric problem [10].
The clinical presentation varies with age at disease on-
set. It ranges between a rapidly progressive and fatal early
onset form, and an adolescent/adult-onset form presenting
as a chronic neurodegenerative disease [9]. We can distin-
guish by onset a pre-/perinatal period (≤3 months), an
early infantile form (onset between 3 months of age and
2 years), a late infantile form (onset between 2 – 6 years),
a juvenile form (6 – 15 years) and an adolescent/adult on-
set form (onset from 15 years of age) [1]. Most patients
become dependent within a mean delay of 8 years [9] and
the majority dies between 10 and 25 years of age [2].
In this article the authors discuss the current findings
on the clinical presentation of NP-C, with focus on psychi-
atric manifestations. We present the case of a 16-year old
girl showing severe psychotic symptomatology with para-
noid delusions and visual and auditory hallucinations.Case presentation
A 16-year old girl, showing psychotic symptomatology
(auditory and visual hallucinations, paranoid delusions)
was admitted to the psychiatric clinic. Psychotic symptom-
atology had started abruptly. MRI and EEG were normal
at this time. Her medical history showed several episodesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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combination of these manifestations, the course of her dis-
ease and the age of onset, made us suspect NP-C.
We hereby present the details of our case and compare
them with findings in recent literature.
Our patient’s medical history showed two unexplained
episodes of splenomegaly (age 1 and age 4). A decrease of
the splenic volume was seen in between episodes, a
complete normalization is documented from the age of 6.
At a pre-school age, she showed a mild delay in develop-
mental milestones. Later on she showed some mild cogni-
tive regression signs during childhood (language problems
and learning difficulties), for which she attended a special-
ized school and had extra speech-therapy. She was treated
with methylphenidate for ‘attention deficit hyperactivity
disorder’ in primary school. She had a normal social and
emotional development.
Evaluation of cognitive functioning showed a slow cog-
nitive decline since infancy. As 7-year old girl she had a
normal IQ (WISC showed total IQ of 78, VIQ: 90; PIQ:
72), at the age of 13 her IQ reached a level of mental re-
tardation (WISC-III showed total IQ of 60).
At age 11 she developed a motor regression with severe
weakness. It was diagnosed as Guillain-Barré syndrome,
type Miller Fisher, due to a mycoplasma pneumonia infec-
tion. CSF-analysis showed an increased protein level. After
revalidation she regained partial, but good, motor capaci-
ties, she was again able to attend school.
At the age of 15 our patient started to show a slow loss
of motor functioning. Ataxia and swallowing problems ap-
peared and revalidation was intensified. Several months
later, at the age of 16, she developed a severe psychotic
syndrome, characterized by auditory hallucinations (hear-
ing people talk to each other), visual hallucinations (in-
sects running on walls, seeing unknown people) and
paranoid delusions (feeling followed, feeling looked at,
feeling threatened), agitation and anxiety. At adminis-
tration of atypical neuroleptic drugs, she started to
show dysarthria that was primarily allocated to the
treatment. The neurological examination showed in-
creased motor loss, swallowing problems and vertical
supranuclear gaze palsy (VSGP).
The combination of psychotic symptoms, progressive
cognitive decline, a history of splenomegaly, VSGP and loss
of motor function, were suspicios for NP-C. Fibroblast fili-
pin staining and DNA sequencing confirmed the diagnosis.
Our patient appeared to be heterozygous for two mutations
in the NPC1-gene. She showed one known frameshift mu-
tation with premature stop codon (Thr124fsX4), which was
clearly deleterious and one unknown missense mutation
(Cys468Gly).
Since she showed major psychotic symptomatology,
neuroleptics were started. Several atypical neuroleptics
where used. Full remission of the psychotic sings was onlyseen with a high dosage (300 mg/ 2 weeks) depot form of
olanzapine. Lorazepam, a psycholeptic drug, was added to
decrease anxiety problems. Confirmation of the diagnoses
was a very difficult period for the patient and her family.
She developed a major depression that was treated with
antidepressants. With this treatment we saw a remission
of the psychiatric symptomatology, the neuromotor deteri-
oration could not be stopped ever since. She is again at-
tending specialized school in a revalidation center. She
lives in her home environment.
Miglustat is the only disease specific treatment. Since
miglustat is not reimbursed in Belgium in the indication
of NP-C and since it is up till now not recognized as
treatment for the psychotic symptoms in NP-C, our pa-
tient is not yet treated.
Discussion
Visceral manifestations in NP-C
Prolonged unexplained neonatal jaundice or cholestasis
and isolated unexplained splenomegaly (historical and/or
current) with/without hepatomegaly are the strongest vis-
ceral indicators for NP-C [6]. As in our patient, patients
often show a history of neonatal jaundice or splenomegaly
during infancy [2,5,9].
The first psychiatric signs
Psychiatric signs and problems are very common in the
juvenil and adult forms of NP-C. As mentioned earlier,
psychiatric signs can be the first presentation of the dis-
ease and can remain isolated for many years [9].
The onset of psychiatric problems can be progressive or
acute, with spontaneous remission and relapse. Children
with juvenile onset (6–15 years) of NP-C often show
school problems (attention difficulties, learning difficulties,
writing problems) [9]. Our patient was treated for ADHD
in primary school.
The leading psychiatric manifestations are cognitive de-
cline and psychosis and they tend to increase in patients
above 16 years of age [6,7]. Our patient showed a signifi-
cant cognitive decline, ranging from a normal intelligence
at age 7, to a level of mental retardation at age 13.
Patients show paranoid delusions, auditory or visual hallu-
cinations, interpretative thoughts, behavioral disturbances,
self-mutilation or social isolation [9]. Schizophrenia-like
psychosis has been reported in up to 25% of the adult pa-
tients with NP-C [4].
Other types of psychiatric disturbances include depressive
syndrome, bipolar disorders and obsessive- compulsive dis-
orders [4], treatment-resistant psychiatric symptoms and
disruptive or aggressive behavior [7]. Our patient devel-
oped in the immediate period after diagnosis a depressive
syndrome.
In a recently published study [11], the prevalence of NP-
C was evaluated in adult patients with psychosis and/or
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out additional neurological or visceral signs suggestive
of NP-C. 3 patients out of the 256 enrolled, were identi-
fied as NP-C positive and in 12 the diagnosis remained
uncertain. The observed frequency was potentially higher
than the incidence in the general population. The authors
suggest an underdiagnosed pool of NP-C in this specific
group of patients.
Neurological signs
Gelastic cataplexia and VSGP are the strongest indica-
tors of NP-C. Ataxia, clumsiness or frequent falls, dys-
arthria and/or dysphagia and dystonia are moderate
indicators. Acquired and progressive spasticity is a weak
indicator. Hypotonia, delayed developmental milestones,
seizures and myoclonus are ancillary neurological mani-
festations [4,6,7].
Our patient only showed VSGP at the age of 16. We
don’t know if it was missed or absent earlier in her life. We
didn’t find any gelastic cataplexia in her medical history.
The wide range of neurological signs seen in NP-C can
mimic other, more common, neurological and psychiatric
diseases. In adults with NP-C reported in the literature,
some initial diagnoses were Alzheimer’s disease, Parkinson’s
disease, schizophrenia, Wilson’s disease, multiple sclerosis,
Creutzfeldt–Jakob disease and Gayet– Wernicke en-
cephalopathy [9]. In our patient, the neurological pres-
entation was thought to be a Guillain-Barré syndrome,
type Miller-Fisher.
Diagnosis
Diagnosis of NP-C is difficult, especially when it presents as
a pure psychiatric disorder [9]. Individual NP-C manifesta-
tions are not specific to the disease, but the combination of
multiple signs and symptoms shows more diagnostic speci-
ficity for NP-C, which may help with disease detection
[7,12]. Diagnosis of NP-C is made by physical and
neurological assessment of the patient, biochemical
tests involving filipin staining of skin fibroblasts, and
genetic sequencing of the NPC1 or NPC2 gene [1,2,4].
Filipin staining and genetic analysis are recommended
as the first-line diagnostic tests, to be carried out in
parallel if possible in order to obtain complementary
information [4].
The physical assessment is focusing on specific combi-
nations of visceral-, neurological- and psychiatric symp-
tomatology. Wijburg [6] developed a Suspicion Index (SI)
tool, ranking specific symptoms within and across do-
mains, including family members who have NP-C. They
provide a risk prediction score to identify patients who
should undergo testing for NP-C [13]. The SI provides a
risk prediction score (RPS) based on NP-C manifestations
within and across 3 domains (visceral, neurological, and
psychiatric). It is a screening tool and is not to be used asa diagnostic tool [7]. Patients with a RPS ≥70 should be re-
ferred to an NP-C center for immediate testing, and scores
from 40 to 69 indicate that further follow-up is required
(and an NP-C center contacted for discussion). Scores
below 40 indicate a low likelihood of NP-C [4].
Neonatal jaundice/cholestasis, splenomegaly, vertical
supranuclear gaze palsy, cataplexy, and cognitive decline/de-
mentia are strong predictors of NP-C, and also parents/sib-
lings or cousins with NP-C [6,7]. Suspicion for NP-C should
be raised when patients present clinical manifestations not
only within, but more importantly across, multiple domains
[7]. The SI tool maintains strong discriminatory power in
patients >4 years but is not as useful for infants <4 years [7].
Our patient had a score of 222 on the SI (age 16). Until
the age of 6, she didn’t show any neurological or psychi-
atric signs. She then started to show minor developmental
delays. A calculation with the SI-score would have given a
result of 126 at the age of 8. She then showed isolated
splenomegaly in the medical history, delayed developmen-
tal milestones and ‘other psychiatric disorders’ (language
and learning difficulties, ADHD). At the age of 11 when
developing a massive motor regression with severe weak-
ness, the SI-score would have been 147.
These findings highlight the need of a thorough medical
examination and assessment of medical history, in all pa-
tients presenting with neurodevelopmental disorders or
delay in development.
Treatment
Patterson et al. give recommendations for diagnosis and
treatment of NP-C. Since no curative treatment is avail-
able, a rigorous symptomatic treatment is advised [7]. Psy-
chiatric symptoms in NP-C are often treatment-resistant
[7]. In our patient, dyskinesia was primarily allocated to
the neuroleptic treatment rather than seen as dystonia, a
mistake that occurs frequently in NP-C [4] and should
trigger awareness about the presence of a disorder of the
basal ganglia [14].
Motor difficulties as ataxia and dysarthria, could wrongly
be allocated to the side-effects of the antipsychotic medica-
tion. It is important to differentiate between drug effects
and those due to the disease. Since a paradoxical effect to
neuroleptic medication is often seen in these patients, one
should consider aborting current treatment instead of in-
creasing dosage. Atypical neuroleptics are proposed as the
first choice treatment when psychotic symptoms occur [4].
Miglustat is currently the only disease-specific treatment
[5]. Miglustat may act as a competitive inhibitor of the en-
zyme glucosylceramide synthase and thereby reduces the
potentially neurotoxic accumulation of gangliosides GM2
and GM3, lactosylceramide and glucosylceramide [1].
Miglustat has an indication in the European Union for
treatment of progressive neurological manifestations in
adult and pediatric patients with NP-C, since 2009 [15].
Wouters et al. Child and Adolescent Psychiatry and Mental Health 2014, 8:20 Page 4 of 4
http://www.capmh.com/content/8/1/20Treatment with miglustat has shown to stabilize neuro-
logical symptoms in NP-C, but should be administered
only when neurological symptomatology is present [4].
In a recently published case report, a complete remis-
sion of the psychotic symptomatology was seen in a pa-
tient with NP-C and psychosis [16]. Replication of these
findings is needed before conclusions are made.Conclusion
NP-C is a severe neurovisceral lipid storage disease. It is
characterized by a specific, but variable manifestation of
visceral, neurological and psychiatric symptoms. Since it
can show as a merely psychiatric illness, child and ado-
lescent psychiatrists should take into account the poten-
tial presence of this underlying disorder.
There could be an underdiagnosis of NP-C patients in
psychiatric populations [11]. Physical examination and as-
sessment of medical history is compulsory when evaluat-
ing children with a neurodevelopmental disorder or delay.
Our patient showed a very slow loss of cognitive func-
tioning, this in the background of one major motor syn-
drome and an acute psychotic decompensation. Genetic
examination showed one previously undescribed mis-
sense mutation (Cys468Gly) in the NPC1-gene.
Patients presenting with any atypical psychiatric dis-
order or any progressive neurological syndrome including
ataxia, early onset dementia or dystonia, in addition to iso-
lated splenomegaly and/or vertical supranuclear gaze palsy
(VSGP) abnormalities should be examined for possible
NP-C [4,14]. The recently developed ‘Suspicion Index tool’
provides a risk prediction score to identify patients who
should undergo testing for NP-C [13].
Patterson et al. [4] provide recommendations concern-
ing diagnosis and treatment of NP-C patients.
Miglustat is the only disease specific medication. It
shows its effects in the treatment of neurological mani-
festations, but is not curative. Early administration of
miglustat could influence the trajectory of the disease.Consent
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